Screener
Jazz Pharmaceuticals JAZZ Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Income taxes payable | 93.7 | 56.3 |
| Total current liabilities | 2,246.6 | 2,242.5 |
| Long-term debt, less current portion | 4,324.2 | 4,328.4 |
| Operating lease liabilities, less current portion | 47.3 | 50.9 |
| Deferred tax liabilities, net | 547.7 | 594.5 |
| Other non-current liabilities | 161.5 | 124.4 |
| Commitments and contingencies (Note 10) | ||
| Shareholders’ equity: |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's operating lease liabilities?
- Jazz Pharmaceuticals (JAZZ) reported operating lease liabilities of $47.3M in Q1 2026.
- How has Jazz Pharmaceuticals's operating lease liabilities changed year-over-year?
- Jazz Pharmaceuticals's operating lease liabilities increased by 22.0% year-over-year, from $38.78M to $47.3M.
- What is the long-term trend for Jazz Pharmaceuticals's operating lease liabilities?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's operating lease liabilities has grown at a -18.3% compound annual growth rate (CAGR), from $140.04M to $50.9M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Jazz Pharmaceuticals's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude